CYP1A2 rs762551: What Your Genotype Means
The rs762551 variant is a common genetic change located in the CYP1A2 gene, which provides instructions for making an enzyme responsible for breaking down caffeine and various medications. This variant is frequently studied for its role in modulating how quickly individuals metabolize caffeine and how they may respond to certain therapeutic drugs.
What each genotype means
Fast caffeine metabolizer
Individuals with this genotype are typically classified as fast metabolizers of caffeine due to higher enzyme inducibility. Research suggests you may clear caffeine from your system more rapidly than those with the C allele, which can influence how you respond to caffeine intake and certain medications. Please discuss any concerns regarding medication dosing or caffeine sensitivity with your clinician or pharmacist.
This is the most common genotype in many populations, carried by approximately 40-50% of individuals of European ancestry.
Intermediate caffeine metabolizer
Carrying one copy of the C allele is associated with reduced CYP1A2 enzyme activity compared to the AA genotype. You may be considered an intermediate metabolizer, meaning caffeine and certain drugs metabolized by this enzyme might remain in your system for a longer duration. Please discuss any concerns regarding medication dosing or caffeine sensitivity with your clinician or pharmacist.
This genotype is common, appearing in roughly 40% of individuals of European ancestry.
Slow caffeine metabolizer
Individuals with this genotype are often classified as slow metabolizers because the C allele is associated with the lowest levels of CYP1A2 enzyme activity and inducibility. This may result in a slower clearance rate for caffeine and certain medications, potentially increasing their physiological effects. Please discuss any concerns regarding medication dosing or caffeine sensitivity with your clinician or pharmacist.
This genotype is the least common of the three, found in approximately 10-15% of individuals of European ancestry.
Understanding the rs762551 Variant
The rs762551 variant is a single-nucleotide polymorphism (SNP) situated within the CYP1A2 gene on chromosome 15. In scientific literature, it is sometimes referred to as the -163C>A polymorphism or associated with the CYP1A2*1F allele. This specific location is critical because it sits in a region that influences the inducibility of the CYP1A2 enzyme. While the baseline activity of the enzyme may not differ significantly between individuals at rest, the presence of the A allele is associated with higher enzyme inducibility when exposed to certain environmental factors, such as smoking or high caffeine intake. This means that for carriers of the A allele, the body may ramp up its production or activity of the enzyme more effectively than in those who carry the C allele, potentially altering the speed at which substances are cleared from the bloodstream.
The Role of the CYP1A2 Enzyme
The CYP1A2 gene encodes a member of the cytochrome P450 superfamily of enzymes, which are primarily located in the liver. These enzymes are the body's primary chemical processing units, responsible for metabolizing a wide array of substances, including dietary components like caffeine and various clinical medications, such as certain antipsychotics, antidepressants, and cardiovascular drugs. By breaking these compounds down into smaller molecules, the liver prepares them for excretion from the body. Because CYP1A2 is a major pathway for clearing these substances, variations in the gene can lead to differences in how long a drug or dietary compound remains active in the system. Understanding these metabolic differences is a key focus of pharmacogenomics, a field that explores how an individual's genetic makeup influences their response to medical treatments.
Research Associations and Evidence Strength
Research into rs762551 has largely focused on its impact on caffeine metabolism, with many studies classifying individuals as 'fast' or 'slow' metabolizers based on their genotype. Evidence suggests that 'fast' metabolizers (often associated with the AA genotype) clear caffeine more rapidly, while 'slow' metabolizers (AC or CC genotypes) may experience longer-lasting effects. Some studies have explored whether these metabolic differences influence athletic performance or cardiovascular outcomes, though the evidence remains mixed and context-dependent. In the realm of pharmacogenomics, the evidence for clinical decision-making is considered limited. While the variant clearly influences enzyme activity, clinical outcomes are often shaped by a complex interplay of genetics, age, sex, smoking status, and concurrent medication use. Consequently, this variant is not currently used as a standalone diagnostic tool for prescribing medications. Always consult with a healthcare provider or pharmacist regarding how your genetic profile might interact with specific medications.
Population Frequency
The distribution of the rs762551 variant varies across different global populations. The A allele is relatively common, with frequencies reported at approximately 65-70% in European populations and 55-60% in East Asian populations. Because the variant is so prevalent, a significant portion of the general population carries at least one copy of the A allele, making it a widely studied marker in human genetics.
What This Information Means for You
Knowing your genotype for rs762551 provides insight into your potential metabolic profile, but it is important to interpret this information with caution. Genetic markers are only one piece of a much larger puzzle; your actual metabolic rate is influenced by many factors, including your diet, lifestyle, and other medications you may be taking. This information should not be used to self-diagnose or to make changes to your medical treatment. If you are curious about how your genetics might affect your response to a specific medication, the most appropriate step is to discuss this with your doctor or a clinical pharmacist. They can provide context based on your full medical history and help you understand whether genetic testing is relevant to your specific health needs.
How common is this variant?
The A allele frequency is approximately 65-70% in Europeans and 55-60% in East Asians, making it a very common variant globally.
Frequently asked questions
Does my rs762551 genotype mean I should stop drinking coffee?
No, your genotype does not dictate your dietary choices. While it may influence how quickly you process caffeine, you should base your caffeine intake on how you personally feel and any advice from your healthcare provider.
Can this SNP predict how I will react to all medications?
No, this SNP only relates to the CYP1A2 enzyme, which processes a specific subset of drugs. It does not predict your response to the vast majority of medications processed by other enzymes in the body.
Is a 'slow' metabolizer genotype a health risk?
Being a 'slow' metabolizer is a normal genetic variation, not a disease. It simply means your body processes certain substances at a different rate, which may be relevant when your doctor is selecting the appropriate dose for a specific medication.
Should I get a genetic test for this variant?
Genetic testing for this variant is generally not recommended for the general public. If you have concerns about how you respond to a specific medication, speak with your doctor, who can determine if pharmacogenetic testing is appropriate for your situation.
Sources & further reading
Educational information only, last refreshed 9/26/2026. Not medical advice — these associations describe population statistics, not individual predictions.
Curious what your genotype is for rs762551?
Upload a raw DNA file from 23andMe, AncestryDNA, MyHeritage, or FamilyTreeDNA and see this variant — plus thousands more — interpreted in your full report.
Get my report — $29Related variants in CYP1A2
This variant in the CYP1A2 gene influences the hepatic metabolism rate of caffeine and is a key marker for individual differences in caffeine clearance.
Intronic marker associated with CYP1A2 enzyme activity and caffeine metabolism rates.
Modulates CYP1A2 inducibility affecting the rate of caffeine metabolism and clearance.
Regulatory variant associated with CYP1A2 enzyme activity, influencing the rate of caffeine metabolism and habitual coffee consumption.
A common variant in the CYP1A2 gene associated with caffeine metabolism rates.
Located in intron 1 of CYP1A2, this variant modulates inducible enzyme activity, altering systemic caffeine clearance and individual susceptibility to caffeine-related blood pressure increases.